18,842 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 18,842 shares of the company’s stock, valued at approximately $188,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Perspective Therapeutics during the 1st quarter worth $15,511,000. Affinity Asset Advisors LLC acquired a new position in Perspective Therapeutics in the 1st quarter valued at $6,069,000. Ally Bridge Group NY LLC bought a new position in Perspective Therapeutics in the 2nd quarter worth $3,951,000. Finally, WealthPLAN Partners LLC acquired a new position in Perspective Therapeutics during the 2nd quarter worth $1,695,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CATX. Royal Bank of Canada lowered their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research report on Friday, August 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Wedbush initiated coverage on Perspective Therapeutics in a report on Tuesday, October 1st. They set an “outperform” rating and a $25.00 price target for the company. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, Bank of America initiated coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 target price for the company. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $21.43.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $12.65 on Friday. The business’s fifty day moving average is $13.87. Perspective Therapeutics, Inc. has a one year low of $2.20 and a one year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. Equities research analysts expect that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.